A Phase 3 clinical trial (NCT07214740) evaluating pegcetacoplan (Syfovre®) for Geographic Atrophy Secondary to Age-related Macular Degeneration reached its primary completion on 2025-12-12. This open-label study focused on the safety of pegcetacoplan delivered via a prefilled syringe.
Background
Pegcetacoplan (Syfovre®) is a drug under investigation for Geographic Atrophy Secondary to Age-related Macular Degeneration. The current trial evaluates its safety in a new delivery method, specifically a prefilled syringe.
Trial design
The completed trial, identified as NCT07214740, is a Phase 3, open-label study. It enrolled 44 participants diagnosed with Geographic Atrophy Secondary to Age-related Macular Degeneration. The primary objective of this study was to evaluate the safety of pegcetacoplan when administered using a prefilled syringe.
What this means
The primary completion of this Phase 3 study indicates that the main data collection period for evaluating the safety of pegcetacoplan in a prefilled syringe has concluded. This step is crucial for advancing the development of new administration methods for existing therapies, potentially improving patient convenience and adherence for those with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Source
Information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT07214740, titled "Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe," was updated on 2025-12-12 on clinicaltrials.gov.